Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Express News | Tianda Pharmaceuticals - Unit Granted Drug Registration Approval of Ibuprofen Suspension by Nmpa
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Tianda Pharmaceutical (00455): “Nicodyl for injection” obtained drug registration certificate
According to the Zhitong Finance App, Tianda Pharmaceutical (00455) issued an announcement. Tianda Pharmaceutical (Yunnan) Co., Ltd. (Yunnan Pharmaceutical), a wholly-owned subsidiary of the company, has obtained a drug registration certificate for “injectable nicordil” issued by the China National Drug Administration. The main component of this product is nicordil, which is a freeze-dried powder injection form. Its indications are mainly acute coronary syndrome such as unstable angina pectoris. Nicordil is a first-line medication for coronary microvascular angina pectoris. It can effectively dilate the coronary arteries and works quickly. It has been included in the “Guidelines for Appropriate Use of Coronary Artery Disease (2nd Edition)” and “Non-ST Segment Elevation Emergency
TIANDA PHARMA: ANNUAL REPORT 2023
TIANDA PHARMA To Go Ex-Dividend On June 13th, 2024 With 0.0026 HKD Dividend Per Share
April 10th - $TIANDA PHARMA(00455.HK)$ is trading ex-dividend on June 13th, 2024. Shareholders of record on June 14th, 2024 will receive 0.0026 HKD dividend per share on June 28th, 2024. The ex-di
Tianda Pharmaceutical (00455) will pay a final dividend of HK0.26 cents per share on June 28
Tianda Pharmaceutical (00455) announced that it intends to make final payments for the year ended December 31, 2023...
TIANDA PHARMA: FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2023CLOSURES OF REGISTER OF MEMBERS
Tianda Pharmaceutical (00455) announced annual results. The loss attributable to shareholders of HK$24.155 million decreased by 41.05% year-on-year
According to the Zhitong Finance App, Tianda Pharmaceutical (00455) announced its annual results for the year ended December 31, 2023. The group obtained revenue of HK$532 million, an increase of 29.77% year on year; loss due to shareholders of the parent company was HK$24.155 million, a decrease of 41.05% year on year; loss per share was 1.12 HK cents, and a final dividend of HK 0.26 cents per share was planned. In the pharmaceutical and medical technology business, benefiting from strong sales growth of the pediatric drug tonibuprofen and the maintenance of ideal sales performance for other major products, this year's revenue was HK$470.7 million (previous financial period: 3.45)
Tianda Pharmaceutical (00455) plans to pay a final dividend of HK$0.0026 per share
Tianda Pharmaceutical (00455) announced that it intends to distribute final shares for the year ended December 31, 2023...
TIANDA PHARMA: FINAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Tianda Pharmaceutical (00455) expects losses in 2023 to be reduced by more than HK$15 million compared to the previous period
Tianda Pharmaceutical (00455) announced that the company's fiscal year settlement date has been changed from March 31 to December 3...
Tianda Pharmaceutical (00455.HK) plans to hold a board meeting on March 26 to approve the annual results
Gelonghui March 14 | Tianda Pharmaceutical (00455.HK) announced that the company will hold a board meeting on March 26, 2024 (Tuesday) to approve (including) the annual results of the company and its subsidiaries for the year ended 31 December 2023.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
CITIC Construction Investment: The innovative drug sector has reached the bottom of the valuation to seize multi-line opportunities and focus on systematized pharmaceutical companies entering the harvest period
CITIC Construction Investment released a research report saying that the innovative pharmaceutical industry is expected to achieve good growth in 2024, and is optimistic about the sector's performance.
No Data